Pot legalisation is creeping across the US state by state, and a major market could be about to join their ranks.

Reports out of New York indicate that lawmakers in the Empire State are close to signing a new bill legalising recreational cannabis use.

There are currently 34 US states that allow the use of medicinal cannabis products, while 15 have legalised recreational use.

If New York made it 16 that would add a major new east coast market for the sale of THC cannabis products.

The first state to legalise marijuana was Colorado back in 2012, and since then many attempts have been made in New York without success.

State legislators have reportedly hammered out most of the details, with a couple of tie-ups related to how people found to be driving under the influence of marijuana should be prosecuted.

The office of under-fire New York governor Andrew Cuomo has projected that legal marijuana sales would contribute an additional $US350m worth of tax revenue to the state.

Legalisation in New York would herald another one of the “winds of change” taking place in US markets, where cannabis investor Mark Bernberg highlighted a number of listed investment opportunities in an interview with Stockhead earlier this month.

On the local front, ASX pot stocks got back on the horse last week as 21 of the 35 companies on Stockhead’s watchlist posted a gain.

That marks a sharp turnaround to the last edition of Weed Week when the sector cooled off at the end of February.

Of those 21, 10 companies posted double digit gains last week as more companies continue to look offshore to build out their medicinal cannabis sales strategies.

They included weekly leader BOD Australia (ASX:BDA), which announced a 62 per cent increase on half-year revenues to $3.3m, underpinned by $1.4m of sales to Hong Kong listed Health and Happiness Group (parent company of Swisse).

The latest weekly, monthly and annual price performance for ASX-listed cannabis stocks:

Scroll or swipe to reveal table. Click headings to sort.

Code Name Price ($) 1W % Ret 1M % Ret 1Y % Ret Market Cap
BDA BOD Australia 0.535 30.5% 12.6% 311.5% $50.3M
MXC MGC Pharmaceuticals 0.073 30.4% -6.4% 265.0% $163.2M
WOA Wide Open Agriculture 0.78 20.9% 2.6% 680.0% $74.1M
IHL Incannex Healthcare 0.215 19.4% -17.3% 481.1% $227.2M
AGH Althea Group 0.54 18.7% 0.9% 237.5% $141.7M
EOF Ecofibre Limited 1.43 12.6% -10.6% -1.7% $208.7M
RNO Rhinomed Ltd 0.135 12.5% 8.0% 22.7% $31.7M
DTZ Dotz Nano Ltd 0.27 12.5% 12.5% 487.0% $105.4M
LGP Little Green Pharma 0.7 12.0% 0.0% 169.2% $93.9M
RGI Roto-Gro Intl Ltd 0.054 10.2% -6.9% -20.6% $14.4M
IDT IDT Australia Ltd 0.19 8.6% -9.5% 90.0% $46.8M
ZLD Zelira Therapeutics 0.068 7.9% -15.0% 112.5% $78.6M
EVE EVE Investments Ltd 0.007 7.7% -12.5% 75.0% $25.0M
BOT Botanix Pharma Ltd 0.12 6.8% -13.0% 67.9% $111.0M
PAL Palla Pharma Ltd 0.5 6.4% -5.3% -16.5% $75.2M
ROO Roots Sustainable 0.02 5.3% -9.1% 17.6% $10.3M
EXL Elixinol Global 0.205 5.1% -12.8% -16.7% $66.1M
AC8 Auscann Grp Hlgs Ltd 0.16 5.0% -14.9% -4.5% $49.1M
NTI Neurotech Intl 0.067 4.7% 9.8% 1575.0% $37.8M
SUD Suda Pharmaceuticals 0.043 2.4% -10.4% 15.4% $16.5M
APH AP Hemp Ltd 0.48 2.1% -3.0% 500.0% $35.8M
LSH Lifespot Health Ltd 0.12 0.0% 0.0% 312.1% $20.2M
MDC Medlab Clinical Ltd 0.295 0.0% -13.2% 47.5% $82.5M
ESE Esense-Lab Ltd 0.018 0.0% 0.0% 260.0% $9.2M
CP1 Cannpal Animal 0.17 0.0% -8.1% 78.9% $15.8M
MMJ MMJ Group Hlds Ltd 0.115 0.0% -17.9% 45.6% $27.6M
CAU Cronos Australia 0.14 0.0% -17.6% 55.6% $6.8M
CAN Cann Group Ltd 0.585 -0.8% -24.5% -6.4% $165.3M
EPN Epsilon Healthcare 0.225 -2.2% -11.8% 7.1% $42.9M
MRG Murray River Grp 0.29 -3.3% -21.6% -51.7% $12.8M
SCU Stemcell United Ltd 0.027 -3.6% 0.0% 170.0% $22.7M
CPH Creso Pharma Ltd 0.19 -5.0% -15.6% 233.3% $181.2M
CGB Cann Global Limited 0.0075 -6.3% -25.0% -6.3% $41.1M
LV1 Live Verdure Ltd 0.235 -7.8% 23.7% 0.0% $9.6M
ECS ECS Botanics 0.053 -8.6% -20.9% 140.9% $24.6M